NCT01738594 - Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2013

Primary Completion Date

October 11, 2016

Study Completion Date

October 11, 2016

Conditions

Recurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeStage I Cutaneous T-cell Non-Hodgkin LymphomaStage IA Mycosis Fungoides/Sezary SyndromeStage IB Mycosis Fungoides/Sezary SyndromeStage II Cutaneous T-cell Non-Hodgkin LymphomaStage IIA Mycosis Fungoides/Sezary SyndromeStage IIB Mycosis Fungoides/Sezary SyndromeStage III Cutaneous T-cell Non-Hodgkin LymphomaStage IIIA Mycosis Fungoides/Sezary SyndromeStage IIIB Mycosis Fungoides/Sezary SyndromeStage IV Cutaneous T-cell Non-Hodgkin LymphomaStage IVA Mycosis Fungoides/Sezary SyndromeStage IVB Mycosis Fungoides/Sezary Syndrome

Interventions

DRUG

carfilzomib

Given IV

DRUG

romidepsin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60611

Northwestern University, Chicago